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Many studies rely on self-reported smoking status. We hypothesized that patients with acute coronary syndrome
(ACS), a smoking-related condition, would be more prone to misclassify themselves as ex-smokers, because of
pressure to quit. We compared patients admitted with ACS with a general population survey conducted in the same
country at a similar time. We determined whether ACS patients who classified themselves as ex-smokers (n5635)
were more likely to have cotinine levels suggestive of smoking deception than self-reported ex-smokers in the
general population (n5289). On univariate analysis, the percentage of smoking deceivers was similar among ACS
patients and the general population (11% vs. 12%, p5.530). Following adjustment for age, sex and exposure to
environmental tobacco smoke, ACS patients were significantly more likely to misclassify themselves (adjusted
OR514.06, 95% CI 2.13–93.01, p5.006). There was an interaction with age whereby the probability of
misclassification fell significantly with increasing age in the ACS group (adjusted OR50.95, 95% CI 0.93–0.97,
p,.001), but not in the general population. Overall, smoking deception was more common among ACS patients
than the general population. Studies comparing patients with cardiovascular disease and healthy individuals risk
introducing bias if they rely solely on self-reported smoking status. Biochemical confirmation should be undertaken
in such studies.
Introduction
Many studies have compared patients with cardio-
vascular disease and healthy individuals in terms of
smoking status. Typically, smoking status is based on
self-classification without biochemical confirmation
because this approach is cheap and easy, and does
not necessarily require face-to-face contact.
Therefore, it is important to confirm not only that
this method is valid but also that there is no
difference in self-reporting between these groups
resulting in bias. The validity of self-reporting is
known to be subject to a social desirability bias,
whereby smokers under the greatest pressure to quit
are more likely to deliberately misclassify themselves
as nonsmokers. If patients with a smoking-related
condition, such as cardiovascular disease, are more
likely to misclassify themselves, studies comparing
patients with cardiovascular disease and healthy
individuals will inevitably introduce bias.
Previous studies have examined the validity of self-
reported smoking status either among healthy
individuals or among those with disease. Meta-
analysis suggests that self-reports are reasonably
accurate in most general population studies, with a
pooled sensitivity and specificity of 88% and 89%,
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respectively (Partick et al., 1994). The negative
predictive value in the general population is around
96% (Newell, Girgis, Sanson-Fisher & Savolainen,
1999). Studies examining patients with newly diag-
nosed cardiovascular disease, or a previous cardio-
vascular event, report negative predictive values
of 81–96% (Atterbring, Herlitz, Berndt, Karlsson
& Hjalmarson, 2001; Jarvis, Tunstall-Pedoe,
Feyerabend, Vesey & Saloojee, 1987; Jarvis,
Primatesta, Erens, Feyerabend & Bryant, 2003;
Wilson, Wallston, King, Smith & Heim, 1993;
Woodward & Tunstall-Pedoe, 1992).
Current smokers who deliberately misclassify
themselves as nonsmokers are traditionally termed
‘‘smoking deceivers.’’ There has been only one
previous study that compared deception rates
between those with cardiovascular disease and the
general public (Woodward & Tunstall-Pedoe, 1992).
Woodward and Tunstall-Pedoe (1992) used data
from the Scottish Heart Health Study to compare
deception rates among 320 male nonsmokers with
diagnosed coronary heart disease, 819 with undiag-
nosed coronary heart disease, and 4,229 with no
coronary heart disease. They demonstrated deception
rates of 8%, 2%, and 2%, respectively (p,0.001). The
trend was similar in women. Their results suggested
that having a smoking-related condition resulted in
an increased likelihood of deceiving. However, they
compared only crude deception rates. There was no
adjustment for potential confounding because of age
differences, and they had no information on expo-
sure to environmental tobacco smoke (ETS). Also,
they were unable to distinguish between ex- and
never-smokers. Previous studies suggest that smok-
ing deception varies with sex, age, and context. A
number of studies have suggested that men are more
likely to be smoking deceivers than women (Assaf,
Parker, Lapane, McKeeney & Carleton 2002;
Bowlin, Morrill, Nafziger, Lewis & Pearson, 1996;
Newell et al., 1999). However, this finding is disputed
by others (Morabia, Berstein, Curtin & Berode,
2001). In a meta-analysis, Patrick et al. (1994)
reported higher deception rates among the young,
which they attributed to age differences in social
undesirability. The aim of our study was to
determine whether patients admitted with acute
coronary syndrome (ACS) were more likely to
misclassify themselves than the general public, and
whether this association was independent of age, sex,
and ETS exposure.
Methods
General population
Data from the general population were collected as
part of the Health Education Population Survey
(HEPS) (NHS Health Scotland, 2004). HEPS is a
pan-Scotland survey undertaken periodically since
1996 to monitor health-related knowledge and
behavior. We used data from the survey undertaken
over 7 months from September 2005. Households
were selected from the Postal Address File using
rolling, multi-stage, clustered random sampling.
Participants were then selected from households
using the first birthday method. Interviewers were
not involved in the health care of participants. An
interviewer-administered questionnaire, on a range
of health behaviors, was completed during a face-to-
face interview in participants’ homes. The smoking
module included self-reported smoking status, date
of cessation, use of nicotine replacement therapy and
exposure to ETS. Samples of unstimulated saliva
were collected using salivettes (cotton wool rolls). A
salivette was placed in the mouth for 3–5 min without
chewing until wet with saliva and then stored in
individual containers at 3uC until testing.
ACS patients
Data were collected prospectively on all patients
admitted with ACS to nine acute Scottish hospitals
over 10 months from May 2005. These hospitals
account for 49% of all ACS admissions in Scotland.
Interviewers were not involved in the health care of
participants. During their hospital admission, parti-
cipants completed an interviewer-administered ques-
tionnaire that included questions on self-reported
smoking status, date of cessation, use of nicotine
replacement therapy, and exposure to ETS. The
wording of these questions was consistent with
the HEPS questionnaire. Residual serum from the
clinical blood samples taken on admission was used
to perform cotinine assays. The samples were
centrifuged and stored locally at 220uC before being
transported on dry ice to the central laboratory for
cotinine assay.
Cotinine assay
In both studies, cotinine was analyzed by ABS
Laboratories Ltd in London, United Kingdom,
using gas chromatography with a specific nitrogen/
phosphorous detector GC-NPD (Feyerabend &
Russell, 1990). Cotinine and the internal standard
5-methyl cotinine were extracted using dichloro-
ethane from a 100-ml sample after alkalization using
sodium hydroxide. The lower limit of detection was
0.1 ng/ml.
Cotinine was assayed in saliva in HEPS and serum
in ACS patients. In a random sample of 605 members
of the general population, Jarvis et al. demonstrated
that saliva cotinine levels were 25% higher than in
serum/plasma, and this ratio applied both at the low
levels attributable to ETS and across the range of
active smoking values (Jarvis et al., 2003). Therefore
we applied cut-offs of 12 ng/ml for serum and 15 ng/
ml for saliva as our objective measure of current
versus nonsmokers (Jarvis et al., 1987).
Definitions
All participating hospitals routinely measured tro-
ponin levels on all patients admitted with suspected
ACS. Therefore, ACS was defined as a patient
admitted as an emergency with cardiac chest pain,
in whom the troponin level was raised in the absence
of a noncardiac cause such as renal failure, throm-
boembolic disease, myocarditis or coronary revascu-
larization. This definition was chosen because it was
unambiguous and could be applied easily and
consistently across all patients in all hospitals.
Nonsmokers were defined as either ex- or never-
smokers. Smoking deceivers were defined as people
who classified themselves as nonsmokers but whose
cotinine level was above the cut-off (12 ng/ml for
serum and 15 ng/ml for saliva). Cotinine levels do not
fall to those of a nonsmoker until around 4 days of
abstinence from smoking (Gilbert, 1993). Therefore,
we excluded from our study ex-smokers who had quit
smoking less than 1 month prior to providing the
sample for cotinine assay.
Statistical methods
We used two-sided tests throughout so as not to
prejudge the direction of any difference. In testing for
differences in summary statistics, we used Mantel–
Haenszel tests, chi-square tests for trend, and Mann–
Whitney U tests for binary, ordinal, and continuous
data, respectively. We defined a dichotomous depen-
dent variable on the basis of whether the cotinine
level exceeded the cut-off value or not, and then used
multivariate logistic regression analysis to identify
the factors associated with this outcome. We tested
for interactions between disease status and the other
covariates. We report actual p values to three decimal
places.
Results
Of the 1,735 patients admitted to hospital with ACS,
666 were excluded because they were current
smokers, and 8 because they were taking nicotine
replacement therapy. Of the remaining 1,061, 635
(60%) classified themselves as ex-smokers and 426
(40%) as never-smokers. The HEPS survey provided
questionnaire and cotinine data on 1,061 members of
the general public. Of these, 309 were excluded
because they were current smokers and 6 because
they were taking nicotine replacement therapy. Of
the remaining 746, 289 (39%) classified themselves as
ex-smokers and 457 (61%) as never-smokers.
Smoking deceivers were more likely to classify
themselves as ex-smokers then never-smokers.
Among self-reported nonsmokers, 82% of those
above the cotinine cut-off classified themselves as
ex-smokers, compared with only 49% below the cut-
off (p,.001). Overall, only 22 (3%) self-reported
never-smokers had cotinine levels above the cut-off
(smoking deceivers) and there was no significant
difference between patients admitted with ACS and
the general population (2% vs. 3%, p5.500). There
was no significant association between disease status
and likelihood of deception on either univariate
(OR51.34, 95% CI 0.57–3.18, p5.501) or multi-
variate (OR51.90, 95% CI 0.62–5.84, p5.262)
logistic regression analysis.
Among self-reported ex-smokers, 103 (11%) had a
cotinine level above the threshold (smoking decei-
vers), with no significant difference between ACS
patients and the general population on univariate
analysis (11% vs. 12%, p5.530). However, the
characteristics of self-reported ex-smokers differed
between ACS patients and the general population. In
comparison with the general population, patients
admitted with ACS tended to be older (median age
73 vs. 54 years, MWU p,.001) and were more likely
to be male (66% vs. 45%, x2 test p,.001). Among ex-
smokers as a whole, 50% of the reported total
duration of ETS was related to exposure in the
subject’s own home. However, there was no statis-
tically significant difference between ACS patients
and the general public in terms of the number of
household members who smoked or reported hours
of ETS exposure. Following adjustment for demo-
graphic differences and exposure to ETS, self-
reported ex-smokers admitted with ACS were
significantly more likely overall to have a cotinine
level above the cut-off level than the general
population (adjusted OR514.06, 95% CI 2.13–
93.01, p5.006) (Table 1).
There was a significant interaction between
ACS admission and age (Table 1, Figure 1). Among
self-reported ex-smokers admitted with ACS, the
Table 1. Multiple logistic regression analysis of the determi-
nants of a cotinine level above cut-off among self-reported
ex-smokers.
OR 95% CI p value
Disease status
General population 1.00 — —
Acute coronary syndrome 14.06 2.13–93.01 .006
Sex
Male 1.00
Female 1.03 0.65–1.61 .909
Age (years) 0.99 0.97–1.01 .320
Number of smokers in household 1.76 1.24–2.51 .002
Weekly exposure to ETS (hr) 1.01 1.00–1.02 .159
Age6disease status 0.96 0.93–0.99 .021
likelihood of cotinine levels being above the cut-off
fell significantly with increasing age (adjusted
OR50.95, 95% CI 0.93–0.97, p,.001). By contrast,
the decline in likelihood of deception with increasing
age was nonsignificant in the general population. As
a result, the difference in risk of deception between
ACS patients and the general population was most
pronounced among younger patients and reduced
with increasing age (Figure 1).
Discussion
Our results suggested that deception was more likely
to take the form of misclassification as an ex-smoker
than never-smoker. This is not surprising, since
smoking history is more difficult to conceal than
current smoking habit. Overall, smoking deception
was more common among ACS patients than the
general population. An observed difference in the
deception rates among patients with coronary heart
disease may be artifact or a real finding. We believe
that our findings are unlikely to be artifactual.
Cotinine is the major metabolite of nicotine, and is
the analyte of choice for measuring exposure to
cigarette smoke (both active and passive) and for
discriminating between smokers and nonsmokers
(Dhar, 2004). It has a sensitivity of 96%–97% and a
specificity of 99%–100% (Jarvis et al., 1987). It is
specific to tobacco, is directly proportional to the
quantity of nicotine absorbed, and the presence of
other compounds does not interfere with estimation
of the marker. It has an appropriate half-life (18–
20 hr), has relatively constant levels during the day, is
amenable to estimation in a number of body fluids
(blood, saliva, and urine), with concentrations highly
correlated between all three fluids (Jarvis et al.,
1987), and is available at concentrations that can be
easily quantified. The same laboratory was used to
assay cotinine in both studies, and used the gold
standard method of gas chromatography with a
specific nitrogen/phosphorous detector GC-NPD
(Feyerabend & Russell, 1990). We excluded from
our study participants on nicotine replacement
therapy, snuff or chewing tobacco, and those who
had quit smoking within the previous month.
Cotinine was assayed in saliva in HEPS and in
serum for ACS patients. Ideally, cotinine would have
been assayed using the same medium in both studies.
However, Jarvis et al. (2003) demonstrated that
applying a ratio of 1:1.25 for serum/plasma:saliva
produces a good correlation across the whole range
of cotinine levels, including both ETS and active
smoking. Furthermore, in our study, very few
participants had cotinine values around the cut-off
values. Across both the general population and ACS
patients combined, only two participants had a
cotinine value in the range 10–20 ng/ml. Therefore,
our results are not sensitive to the cut-off values
applied.
Forewarning participants that smoking status will
be confirmed biochemically may result in modifica-
tion of smoking behavior to avoid detection.
However, Jarvis et al. (1987) demonstrated that
97% of current smokers smoked on the day of their
test. Therefore, deliberate avoidance of detection
would require 2–4 days of atypical abstinence.
Among ACS patients, cotinine was assayed on
residual clinical samples obtained on admission and
prior to recruitment to the study. In HEPS, the
salivette was used on the same day that information
was recorded on self-reported smoking status.
Therefore, neither study afforded the opportunity
to modify behavior to appear consistent with self-
reported status. Deception rates vary according to
whether information is collected by face-to-face
Figure 1. Probability of self-reported ex-smokers having a cotinine above the cut-off by age. Example is for a man with
no current smokers in the same household and total ETS exposure per week equivalent to the median (1 hr).
interview or telephone interview and whether the
interviewer in involved in the participant’s clinical
management (Galobardes et al., 1998; Luepker,
Pallonen, Murray, Pirie, 1989). However, both
studies employed face-to-face interviews with
research staff not involved in the care of participants.
Both studies recruited participants over a similar
period, and both completed recruitment prior to the
Scottish ban on smoking in public places, which may
have impacted on social desirability.
Etzel (1990) suggested that there may be difficulty
using cotinine to distinguish between very light active
smoking and regular passive smoking. However, Lee
(1988) reported that even heavy exposure to passive
smoke rarely results in plasma cotinine levels above
10ng/ml. We were able to demonstrate that there
were no differences between ex-smokers admitted
with ACS and ex-smokers in the general population
in terms of household and overall exposure to ETS
and we adjusted for ETS exposure when comparing
deception rate among ACS patients and the general
population. We included age in our model and
demonstrated a significant interaction between age
and deception. Metabolism of cotinine is signifi-
cantly slower in black smokers than white smokers.
However, well over 99% of the Scottish population is
white so we did not need to adjust for race.
A real difference among those with cardiovascular
disease is plausible because of a social acceptability
bias (Partick et al., 1994). Studies have demonstrated
a significantly higher deception rate among people
attending a smoking cessation programme and
among others advised to quit smoking (Murray,
Connett, Lauger & Voelker 1993; Ohlin, Lundh &
Westling, 1976; Sillett, Wilson, Malcolm & Ball,
1978). People with a smoking-related disease are
under greater pressure to quit. They may feel guilty
that their condition is self-inflicted and that failure to
quit demonstrates a lack of gratitude to health care
workers. Alternatively, they may be concerned that
treatment will be withheld if they fail to comply with
smoking advice.
In general, self-reported smoking status is a
satisfactory tool for large-scale population studies
where biochemical confirmation is not feasible or is
too expensive. However, when comparing patients
with a smoking-related condition and healthy indi-
viduals, we need to be aware that the former are
under greater pressure to quit smoking and therefore
are more likely to deliberately misclassify themselves
as nonsmokers. Some investigators have employed a
‘‘bogus pipeline’’ approach, in which study partici-
pants are advised incorrectly that their smoking
status will be confirmed by either corroboration or
biochemical tests. This may be helpful in reducing
deception, or may simply result in short-term modifi-
cation of smoking behavior. Ideally, biochemical
confirmation should be used in all participants in
studies comparing people with and without a
smoking-related condition. If this is not feasible,
biochemical validation should, at least, be under-
taken in a sub-group to either confirm that the results
are free from bias, or to quantify and correct for bias
where it exists.
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